The research base
Every figure, and where it comes from
Nothing on CureCircle is a number we typed in. Each figure is an observation from a published source, kept with the source’s own words, or arithmetic over observations that names them. A daily check re-reads every source.
- Observations
- 586
- Sources
- 293
- Confirmed by the daily check
- 551
- Last read
- 2026-11-06
1. What the platform concludes
What a typical contribution is worth, per licence
A complete story plus one year of the records the condition’s guideline says patients get, valued by the benchmark below.
2. The figures they are computed from
Unit prices, premiums and rates
Value of one patient record, per licenceDerived$23Your health story: value per storyDerived$23Lab results: value per test resultDerived$0.24Repeated lab results: value per test resultDerived$0.24Scan reports: value per reportModelling choice$2.79Scan images: value per scanDerivedno evidence yetDoctor's letters: value per letterModelling choice$3.49Pathology reports: value per reportModelling choice$3.49Medication history: value per medicationModelling choice$2.33Vaccination record: value per vaccinationModelling choice$0.70ECG: value per recordingModelling choice$1.86Health record extract: value per patient recordDerived$79Insurance claims: value per patient recordDerived$1.89Whole genome or exome: value per genomeDerived$20Consumer DNA test: value per genotypeDerived$17Wearable data: value per dayDerived$1.00Glucose sensor data: value per dayDerived$3.43Symptom diary: value per entryModelling choice$2.33Health questionnaires: value per questionnaireModelling choice$1.86Rarity premium for rare conditionsMeasured2.88xRichness premium for linked kinds of dataDerived3xA patient's time in research, per hourMeasured$100A rare-condition patient's time in research, per hourMeasuredno evidence yetClinicians training AI, per hourMeasured$120
Kinds of health data
Conditions
Long COVIDMigraineType 2 diabetesType 1 diabetesAsthmaCOPDHigh blood pressureCoronary heart diseaseHeart failureAtrial fibrillationStrokeChronic kidney diseaseDepressionAnxietyBipolar disorderADHDBurnoutME/CFSFibromyalgiaIrritable bowel syndromeCrohn's diseaseUlcerative colitisCeliac diseaseEndometriosisPCOSInfertilityRheumatoid arthritisLupusMultiple sclerosisPsoriasisEczemaAcneHypothyroidismOsteoarthritisBack painBreast cancerProstate cancerColorectal cancerLung cancerParkinson's diseaseAlzheimer's diseaseEpilepsyLyme diseaseObesitySleep apneaCystic fibrosisEhlers-Danlos syndromeSickle cell diseaseHuntington's diseaseALSGoutOsteoporosisPsoriatic arthritisAnkylosing spondylitisSjögren's syndromeGlaucomaMacular degenerationTinnitusMyasthenia gravisNarcolepsyPOTSPTSDOCDSchizophreniaEating disordersAutismHIVHepatitis BHepatitis CFatty liver diseaseAcid reflux (GERD)Kidney stonesMenopauseGestational diabetesPreeclampsiaIron deficiency anaemiaSarcoidosisPulmonary fibrosisChronic painThyroid cancerLeukaemiaLymphomaMelanoma
3. The observations
Every figure, by topic
What health data sells for (35)
Continuous glucose monitor data from a pregnant participant, payment per day with glucose values$1.50 for every day you wore the sensor with glucose valuesClinicalTrials.gov NCT06957028, informed consent form: CGM for early detection and management of hyperglycemia in pregnancy · checkedCPRD linked hospital data (Hospital Episode Statistics, ONS death registration) added to a primary care study, per linked dataset£4,400 per datasetCPRD, pricing (prices applicable from April 2023, excluding VAT; read from an Internet Archive copy)CPRD Basic multi-study annual licence to UK primary care data, non-commercial£45,000CPRD, pricing (prices applicable from April 2023, excluding VAT; read from an Internet Archive copy)CPRD Full multi-study annual licence to UK primary care data (GOLD and Aurum), commercial£363,000CPRD, pricing (prices applicable from April 2023, excluding VAT; read from an Internet Archive copy)Wearable and health-app activity data shared by a member with Evidation, reward per day at the maximum daily pointsup to 100 points per day; 10,000 points = $10Evidation, blog: how does Evidation work, collecting points · checkedNHS EHR/EMR data, estimated market value per patient record<£100EY, How we can place a value on health care data (19 July 2019) · checkedNHS patient record linked with genomic and phenotypic data, estimated market value per record£1000–5000EY, How we can place a value on health care data (19 July 2019) · checkedGoogle's price for Fitbit spread over Fitbit's active users (whole-company acquisition, arithmetic over two stated numbers)approximately $2.1 billionFitbit, Inc. Form 8-K Exhibit 99.1, Fitbit to be acquired by Google (1 November 2019), sec.gov · checkedGenentech access to 23andMe genetic and phenotypic database for Parkinson's target discovery$10 million upfrontFierce Biotech, 23andMe strikes $60M Genentech deal to continue pivot to database-driven R&D (12 January 2015)GSK one-year nonexclusive licence to 23andMe de-identified genetic data, plus analysis services$20 million upfront23andMe press release, 23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK (30 October 2023) · checkedGSK expanded access to the Tempus patient data platform for drug discovery and trial design$70 millionBioSpace, GSK Expands AI Footprint with $70M Tempus Deal (18 October 2022) · checkedHCUP National Inpatient Sample 2018, one year of US hospital discharge data (non-student price)$750AHRQ HCUP Nationwide Databases catalog, July 2021 · checkedContinuous glucose monitor data from a young person with type 1 diabetes, payment per 14-day CGM data collection, per day$75 for each 3-month CGM data collectionClinicalTrials.gov NCT05413239, HAPPY T1D (Joslin Diabetes Center and Stanford), informed consent and assent form (30 January 2023) · checkedLab results record sold through the MediPact researcher marketplace$0.24 per recordMediPact, guide for researchers (pricing table) · checkedNHS England bespoke data linkage charge, per dataset per dissemination£2862NHS England, Data Access Request Service (DARS) charges, from 1 April 2026 (read from a mirror)One AI data buyer's listed range for de-identified imaging studies and diagnostic tests with reports, per dataset$80,000 to $620,000OpenTrain, company data licensing for imaging and diagnostics centers · checkedPRA Health Sciences' price for Symphony Health spread over the lives in its claims-based data asset (whole-company acquisition, arithmetic over two stated numbers)$530 millionPRA Health Sciences, Form 8-K Exhibit 99.1, PRA Health Sciences to acquire Symphony Health Solutions (7 August 2017), sec.gov · checkedRecursion licence of Tempus de-identified clinical and molecular records for AI model training, annual fee$22.0 million and $42.0 millionRecursion Pharmaceuticals Form 8-K, 9 November 2023 (Tempus master agreement) · checkedRecursion licence of Tempus de-identified records, total over the five-year term$160.0 millionRecursion Pharmaceuticals Form 8-K, 9 November 2023 (Tempus master agreement) · checkedRegeneron purchase of the 23andMe assets, including its consumer genetic biobank, out of bankruptcy$256 millionQuartz, 23andMe just got bought out of bankruptcy (May 2025)Regeneron price for 23andMe spread over the users who paid for the ancestry test (arithmetic over two stated numbers)$256 millionQuartz, 23andMe just got bought out of bankruptcy (May 2025)Sequencing one exome (cost of producing genome-level data) in the Regeneron and GSK project on UK Biobank volunteersestimated cost of $150 million if all 500,000 participants are sequencedGEN, Regeneron, GSK, UK Biobank launch gene sequencing collaboration (23 March 2017) · checkedEarly exclusive access to UK Biobank exome sequences, price paid by each pharmaceutical company in the Regeneron-led consortium, per exome$10 millionRegeneron press release (PR Newswire, 8 January 2018), as carried by BioSpace: Regeneron forms consortium of leading life sciences companies with UK Biobank · checkedAnnual licence for large closed-network private-payer claims data, all therapeutic areas$400k–$800kDagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design · checkedAnnual licence for large closed-network private-payer claims data, one therapeutic area$100k–300kDagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design · checkedStructured electronic health record data licence, one therapeutic area$1–3 millionDagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design · checkedSpecialty unstructured EHR data needing extensive curation, one therapeutic area$3–5 millionDagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design · checkedPathos licence fee spread over the size of the Tempus database (arithmetic over two stated numbers)$200 millionTempus AI, Inc. Form 10-K for fiscal year 2025 · checkedPathos AI licence of Tempus de-identified multi-modal oncology dataset to build a foundation model, three years$200 millionTempus AI, Inc. Form 10-K for fiscal year 2025 · checkedUK Biobank Tier 1 data access (questionnaires, physical measurements, health outcome phenotypes, linked health data), first three years£3,000UK Biobank, Fees (read from an Internet Archive copy, 2025; fees exclude VAT)UK Biobank Tier 2 data access (adds assays, proteomics, measured and imputed genotypes), first three years£6,000UK Biobank, Fees (read from an Internet Archive copy, 2025; fees exclude VAT)UK Biobank Tier 3 data access (adds imaging, whole genome and whole exome sequence data), first three years£9,000UK Biobank, Fees (read from an Internet Archive copy, 2025; fees exclude VAT)UK Biobank whole genome sequencing project: money paid by four pharmaceutical companies, per genome£100 millionGOV.UK (BEIS and UKRI), World's largest genetics project to tackle deadly diseases launches (11 September 2019) · checkedWearable sensor data (heart rate, movement, breathing, sleep) contributed by a participant in a university study, reward per day of data$1University of Maryland, CATCH study (acute respiratory infection), consent form for the wearable portion (IRBNet package dated 21 September 2019)Fitbit smartwatch wear data from a participant in a physical activity study, payment for wearing it day and night through the study, per day$35ClinicalTrials.gov NCT06125964, University of Southern California eMOTION study, informed consent form (version 23 January 2024) · checked
What people are paid (40)
Chronic lymphocytic leukemia patients, 90-minute research interview plus a short journal$400CLL Society, Paid Research Opportunity (January 2023) · checkedDataAnnotation expert contract roles, advertised pay$75–$125+/hrDataAnnotation, Does Data Annotation pay well · checkedPhase I trials: median compensation to US healthy volunteers per trialUS$3070Fisher et al., Clinical Trials 2021, Phase I trial compensation: How much do healthy volunteers actually earn from clinical trial enrollment? · checkedPayments offered to research subjects in 467 US protocols at 11 IRBs, overall median$155Grady et al., Contemporary Clinical Trials 2005, An analysis of U.S. practices of paying research participants · checkedIncentive for medical professionals in a 60-minute research session$200-400/hourGreat Question, Research incentives: what to pay participants in 2026 (updated October 2026) · checkedHandshake AI Medicine Domain Expert contract role, pay range$110.00 – $140.00 per hourHandshake AI job listing, Medicine Domain Expert (AI Research contract; listing says posted 6+ months ago) · checkedHandshake AI contract role for physicians (MD or DO with patient care experience), pay range$175 – $200 per hourHandshake AI job listing, Physicians (listing says posted 6+ months ago) · checkedGerman app and wearable users' stated minimum monthly payment for patient-generated health data of all types, from pharmaceutical and device companies237.30€/monthHeidel, Hagist and Schlereth, PLOS ONE 2021, Pricing through health apps generated data: digital dividend as a discrete choice experiment (Germany) · checkedGerman app and wearable users' stated minimum monthly payment for patient-generated health data of all types, from universities145.66€/monthHeidel, Hagist and Schlereth, PLOS ONE 2021, Pricing through health apps generated data: digital dividend as a discrete choice experiment (Germany) · checkedAdvanced or metastatic kidney cancer patients, 90-minute phone interview plus a 5-day journal$400Kidney Cancer Association press room, market research recruitment (6 June 2015; read from an Internet Archive copy)LunaDNA: value of consumer genotyping data contributed by a person, paid in company shares50 sharesThinkAdvisor, Share your DNA, get shares (5 October 2018; read from an Internet Archive copy)LunaDNA: value of a whole genome contributed by a person, paid in company shares$21ThinkAdvisor, Share your DNA, get shares (5 October 2018; read from an Internet Archive copy)Mercor posted rate for board-certified MD or DO with an active unrestricted licence$115 to $150 an hourSecond Talent, Domain expert AI trainer rates (October 2026) · checkedMercor standing clinician network (health professions), posted project rates$60 to $180 an hourMercor job listing, Physician (clinician network)Advanced expert patient or caregiver engagement with a sponsor, fair market value range$110 - $235National Health Council, Fair Market Value Hourly Rate Methodology (updated June 2024) · checkedExpert patient or caregiver engagement with a sponsor, fair market value range$90 - $165National Health Council, Fair Market Value Hourly Rate Methodology (updated June 2024) · checkedIndividual patient or caregiver engagement with a sponsor, fair market value range$55 - $120National Health Council, Fair Market Value Hourly Rate Methodology (updated June 2024) · checkedOutlier (Scale AI) medicine expert role, advertised pay range$35-$45 USD/hrOutlier, training AI with your medical expertise (read from an Internet Archive copy)Outlier (Scale AI) radiology expert role, advertised payup to $120 USD/hrOutlier, Radiology expert page (read from an Internet Archive copy)Minimum hourly pay for research participants on the Prolific platform$8Prolific, Payment principles · checkedRecommended hourly pay for research participants on the Prolific platform$12Prolific, Payment principles · checkedPatient or caregiver 30-minute online survey$50Rare Patient Voice, Time is money · checkedPatient or caregiver 60-minute telephone interview$100Rare Patient Voice, Time is money · checkedAlopecia areata patients, 90-minute phone interview$150Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedAlzheimer's disease patients over 65 and caregivers, 30-minute phone interview$60Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedAmyloidosis (ATTR-CM or ATTR-PN) patients, 60-minute phone interview$120Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedAtopic dermatitis (eczema) patients, 60-minute phone interview$120Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedColorectal cancer patients, 30-minute online survey$60Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedCOPD patients, 60-minute phone interview$120Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedCrohn's disease, microscopic colitis and ulcerative colitis patients, 90-minute phone interview plus confirmation of diagnosis$210Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedEndometrial cancer patients, 90-minute phone interview$200Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedHonorarium for patients and caregivers in market research studies, hourly rate$100 per hourRare Patient Voice, Time is money · checkedHonorarium for patients and family caregivers in market research studies, typical hourly rate$120 per hourRare Patient Voice, Time is money · checkedHuntington's disease patients and caregivers, 60-minute phone interview$120Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedSystemic lupus erythematosus patients (non-Caucasian), 30-minute online survey$60Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedMetastatic breast cancer patients, 60-minute phone interview$120Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedRheumatoid arthritis patients, 30-minute online survey$50Rat Race Rebellion, 100+ Paid Health-Related Studies (a promotional list of Rare Patient Voice studies, 17 July 2025) · checkedAverage incentive for a 30-minute remote research session$49.80/sessionUser Interviews, The Ultimate Guide to User Research Incentives (updated January 2025) · checkedRecommended incentive for high-wage professionals such as doctors, dentists and lawyers$150-225/hourUser Interviews, The Ultimate Guide to User Research Incentives (updated January 2025) · checkedModerated consumer research session, most common incentive$100/hourUser Interviews, The Ultimate Guide to User Research Incentives (updated January 2025) · checked
What research spends per patient (9)
Advanced orphan drug trials (four companies), company-reported per-patient trial cost$137,000 to over $5MMHealth Advances, Orphan Drug Development: What are the Real Costs? (10 April 2019; read from an Internet Archive copy)Phase 3 oncology trials, per-patient cost (PhRMA 2015, as cited by Health Advances)$69,000Health Advances, Orphan Drug Development: What are the Real Costs? (10 April 2019; read from an Internet Archive copy)Average per-patient Phase 3 trial cost across 1,680 trials (PhRMA and Battelle, as cited by Health Advances)$42,000Health Advances, Orphan Drug Development: What are the Real Costs? (10 April 2019; read from an Internet Archive copy)Pivotal trials behind 59 novel FDA approvals in 2015 and 2016, estimated median cost per patient$41,117AJMC, More than 100-fold cost differences found for pivotal trials (September 2018), reporting Moore et al., JAMA Internal Medicine 2018 · checkedPivotal trial of uridine triacetate for a rare hereditary metabolic disorder, 4 patients$2.1 millionAJMC, More than 100-fold cost differences found for pivotal trials (September 2018), reporting Moore et al., JAMA Internal Medicine 2018 · checkedAverage per-patient clinical trial cost, all drugs (Battelle study for PhRMA)$36,500Knowledge Ecology International, post of 10 April 2016 citing Table A-1 of a Battelle study for PhRMA · checkedAverage per-patient clinical trial cost, cancer drugs (Battelle study for PhRMA)$59,500Knowledge Ecology International, post of 10 April 2016 citing Table A-1 of a Battelle study for PhRMA · checkedMedian cost per recruited patient across 30 recruitment cost articles (converted to 2017 USD)USD 409Speich et al., Journal of Clinical Epidemiology 2018, Systematic review on costs and resource use of randomized clinical trials · checkedOverall cost of a randomized clinical trial per patient across 16 articles (converted to 2017 USD)USD 43-103,254 per patientSpeich et al., Journal of Clinical Epidemiology 2018, Systematic review on costs and resource use of randomized clinical trials · checked
What makes health data worth more (11)
Premium on research incentives for physicians, pharmacists and clinical specialists over general professional ranges40 to 80 percentCleverX, Research incentive rates by seniority (benchmarks) · checkedCPRD single-study fee for cancer registration plus systemic therapy and radiotherapy linked data against cancer registration data alone£4,400 and £16,300CPRD, pricing (prices applicable from April 2023, excluding VAT; read from an Internet Archive copy)NHS patient record linked with genomic and phenotypic data against EHR/EMR data alonebetween £1000–5000 per record when combined with genomic and phenotypic dataEY, How we can place a value on health care data (19 July 2019) · checkedCompany-reported per-patient cost in advanced orphan trials against the average Phase 3 per-patient cost$137,000 to over $5MM against $42,000Health Advances, Orphan Drug Development: What are the Real Costs? (10 April 2019; read from an Internet Archive copy)Stated price for patient-generated health data, pharmaceutical and device companies against universities237.30€/month and 145.66€/monthHeidel, Hagist and Schlereth, PLOS ONE 2021, Pricing through health apps generated data: digital dividend as a discrete choice experiment (Germany) · checkedLunaDNA share value of a whole genome against consumer genotyping data300 shares and 50 sharesThinkAdvisor, Share your DNA, get shares (5 October 2018; read from an Internet Archive copy)Advanced expert patient or caregiver against individual patient or caregiver, fair market value per hour$110 - $235 and $55 - $120National Health Council, Fair Market Value Hourly Rate Methodology (updated June 2024) · checkedPer-patient trial cost of orphan drugs against non-orphan drugs, Phase 3 (EvaluatePharma data)2.5:1Jayasundara et al., Orphanet Journal of Rare Diseases 2019, Estimating the clinical cost of drug development for orphan versus non-orphan drugs · checkedCurated unstructured EHR data licence against claims data licence, per therapeutic area per year (price ladder)$100k–300k per therapeutic area (claims) and $3–5 million per TA (curated EHR)Dagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design · checkedStructured EHR data licence against claims data licence, per therapeutic area per year (price ladder)$100k–300k per therapeutic area (claims) and $1–3 million per TA (structured EHR)Dagenais et al., Clinical Pharmacology & Therapeutics 2022, Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design · checkedUK Biobank Tier 3 (adds imaging and sequence data) against Tier 1 (questionnaires, measurements, linked health data), first three years£3,000 and £9,000UK Biobank, Fees (read from an Internet Archive copy, 2025; fees exclude VAT)
People living with a condition (104)
People aged 30 to 79 with COPD (GOLD definition), 2019391·9 millionAdeloye et al., Global, regional, and national prevalence of, and risk factors for, COPD in 2019, Lancet Respir Med 2022 · checkedCrude worldwide prevalence of ALS4.42 per 100,000 populationJournal of Neurology 2020, Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis · checkedPrevalence of sarcoidosis, Sweden, 2013 (two or more sarcoidosis-coded visits)160 per 100 000Arkema et al., Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden, Eur Respir J 2016 · checkedPeople living with multiple sclerosis, worldwide2.8 millionMultiple Sclerosis Journal 2020, Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition · checkedAdults aged 30 to 69 with mild to severe obstructive sleep apnoea, worldwide936 millionLancet Respiratory Medicine 2019, Estimation of the global prevalence and burden of obstructive sleep apnoea (Benjafield et al.) · checkedPeople living with ALS in the United States, 2018 (National ALS Registry)6.6 per 100,000Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2023, Prevalence of amyotrophic lateral sclerosis in the United States, 2018 · checkedUS adults with chronic pain (pain on most days or every day for 3 months), 202151.6 millionRikard et al. (CDC), Chronic Pain Among Adults: United States, 2019-2021, MMWR 2023 · checkedPeople living with cystic fibrosis in the United States, 202038,804Journal of Cystic Fibrosis 2023, Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry · checkedIndividuals worldwide estimated to have long COVIDAt least 65 millionDavis et al., Long COVID: major findings, mechanisms and recommendations, Nat Rev Microbiol 2023 · checkedExpected number of people with ankylosing spondylitis in Asia4.63-4.98 millionDean et al., Global prevalence of ankylosing spondylitis, Rheumatology (Oxford) 2014 · checkedExpected number of people with ankylosing spondylitis in Europe1.30-1.56 millionDean et al., Global prevalence of ankylosing spondylitis, Rheumatology (Oxford) 2014 · checkedMean prevalence of ankylosing spondylitis in Europe (36 eligible studies across continents)23.8 in EuropeDean et al., Global prevalence of ankylosing spondylitis, Rheumatology 2014Overall prevalence of Ehlers-Danlos syndromes1 in 5000The Ehlers-Danlos Society, Are the Ehlers-Danlos Syndromes and Hypermobility Spectrum Disorders Rare or Common? · checkedMean prevalence of cystic fibrosis in the 27 EU countries0.737/10,000Farrell, The prevalence of cystic fibrosis in the European Union, J Cyst Fibros 2008 · checkedCurrent prevalence of obsessive-compulsive disorder in adults, pooled worldwide1.1%Fawcett, Power and Fawcett, Women Are at Greater Risk of OCD Than Men: A Meta-Analytic Review of OCD Prevalence Worldwide, J Clin Psychiatry 2020 · checkedShare of people in Europe with hypothyroidism, diagnosed and undiagnosed3.05%Journal of Clinical Endocrinology & Metabolism 2014, The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis · checkedPeople living with inflammatory bowel disease (Crohn's disease and ulcerative colitis together) worldwide, 20176·8 millionLancet Gastroenterology & Hepatology 2020, The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017 (GBD 2017) · checkedPrevalent cases of acne vulgaris, worldwide, 2019231·2 millionBritish Journal of Dermatology 2022, Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories (GBD 2019) · checkedPrevalent cases of atrial fibrillation/flutter worldwide, 202152.55 millionGlobal burden and health inequality of atrial fibrillation/atrial flutter from 1990 to 2021 (GBD 2021) · checkedPeople with atopic dermatitis, worldwide, 2021129 millionLancet Respiratory Medicine 2025, Global, regional, and national burden of asthma and atopic dermatitis, 1990-2021 (GBD 2021) · checkedPeople on the autism spectrum worldwide in 202161·8 millionGBD 2021 Autism Spectrum Collaborators, The global epidemiology and health burden of the autism spectrum, Lancet Psychiatry 2025 · checkedShare of diabetes cases that are type 2, worldwide, 202196·0%GBD 2021 Diabetes Collaborators, Lancet 2023 · checkedPeople with anaemia due to dietary iron deficiency worldwide, 2021444 million ... 825 millionGBD 2021 Anaemia Collaborators, Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021, Lancet Haematol 2023 · checkedGlobal prevalence of dietary iron deficiency (GBD 2021)16.7%Lee et al. (GBD 2021 Dietary Iron Deficiency Collaborators), Global, regional and national burden of dietary iron deficiency from 1990 to 2021, Nat Med 2025 · checkedPeople living with gastroesophageal reflux disease (GERD) worldwide, 2021825.60 millionChen et al., Global, regional and national burdens of gastroesophageal reflux disease from 1990 to 2021 and projections to 2050 (GBD 2021), BMC Public Health 2025 · checkedPeople living with gout, 202055·8 millionGBD 2021 Gout Collaborators, Global, regional, and national burden of gout, 1990-2020, and projections to 2050, Lancet Rheumatol 2024 · checkedPeople with interstitial lung disease and pulmonary sarcoidosis worldwide, 2021 (GBD category)4306627.72Zhang et al., Global, regional and national burden of interstitial lung disease and pulmonary sarcoidosis, 1990-2021 and projection to 2040, Front Med 2025 · checkedPeople with metabolic dysfunction-associated steatotic liver disease (MASLD) worldwide in 20211.27 billionDanpanichkul et al., The Rising Global Burden of MASLD and Other Metabolic Diseases (2000-2021), United European Gastroenterol J 2025 · checkedPrevalent cases of migraine worldwide, 20211.158 billionThe global and regional burden and trends of migraine from 1990 to 2021: Global Burden of Disease Study 2021 · checkedWomen aged 15 to 49 living with polycystic ovary syndrome worldwide, 202165.77 millionFrontiers in Public Health 2025, Global burden of polycystic ovary syndrome among women of childbearing age, 1990-2021 (GBD 2021) · checkedPeople with thyroid cancer worldwide, 2021 (GBD prevalent cases)2 millionZhang et al., Epidemiological study of thyroid cancer at global, regional, and national levels from 1990 to 2021 (GBD 2021), Front Endocrinol 2025 · checkedPeople living with type 2 diabetes worldwide, 2021 (diabetes cases times the type 2 share, both from GBD 2021)529 million ... 96·0%GBD 2021 Diabetes Collaborators, Global, regional, and national burden of diabetes from 1990 to 2021, Lancet 2023Adults aged 20 and older with chronic kidney disease, 2023788 millionGBD 2023 Chronic Kidney Disease Collaborators, Lancet 2025 · checkedPooled prevalence of burnout among healthcare workers during COVID-1952%Frontiers in Psychiatry 2021, A Systematic Review and Meta-Analysis of Burnout Among Healthcare Workers During COVID-19 · checkedPeople alive within 5 years of a breast cancer diagnosis, worldwide, 20248 162 335IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedPeople alive within 5 years of a colorectal cancer diagnosis, worldwide, 20245 909 291IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedPeople alive within 5 years of a Hodgkin lymphoma diagnosis, worldwide, 2024295 417IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedPeople alive within 5 years of a leukaemia diagnosis, worldwide, 20241 488 016IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedPeople alive within 5 years of a lung cancer diagnosis, worldwide, 20243 568 718IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedPeople alive within 5 years of a lymphoma diagnosis (Hodgkin and non-Hodgkin together), worldwide, 2024295 417 ... 1 721 285IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer sitePeople alive within 5 years of a melanoma of the skin diagnosis, worldwide, 20241 309 107IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedPeople alive within 5 years of a non-Hodgkin lymphoma diagnosis, worldwide, 20241 721 285IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedMen alive within 5 years of a prostate cancer diagnosis, worldwide, 20245 180 908IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedPooled global prevalence of idiopathic pulmonary fibrosis (IPF)17.7Golchin et al., Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis, BMC Pulm Med 2025 · checkedAdults living with pain worldwide (estimate)20%Goldberg and McGee, Pain as a global public health priority, BMC Public Health 2011 · checkedIndividuals worldwide with type 1 diabetes, 2021about 8·4 millionGregory et al., Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040, Lancet Diabetes Endocrinol 2022 · checkedPeople estimated to be living with cystic fibrosis across 94 countries162,428Journal of Cystic Fibrosis 2022, Worldwide rates of diagnosis and effective treatment for cystic fibrosis · checkedPrevalence of postural tachycardia syndrome (POTS) across four published reportsapproximately 0.2%Sheldon et al., 2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, Heart Rhythm 2015 · checkedGlobal standardized prevalence of gestational diabetes (IADPSG criteria), IDF Diabetes Atlas 202114.0%Wang et al., IDF Diabetes Atlas: Estimation of Global and Regional Gestational Diabetes Mellitus Prevalence for 2021 by IADPSG Criteria, Diabetes Res Clin Pract 2022 · checkedPrevalent cases of ischaemic heart disease worldwide, 2019197 millionRoth et al., Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019, J Am Coll Cardiol 2020 · checkedShare of the US population estimated to have postural orthostatic tachycardia syndrome (POTS)0.1% to 1%Chung and Raj, Postural Orthostatic Tachycardia Syndrome (POTS): A Review, JAMA 2026 · checkedAdults living with any tinnitus worldwidemore than 740 million adultsJarach et al., Global Prevalence and Incidence of Tinnitus: A Systematic Review and Meta-analysis, JAMA Neurol 2022 · checkedLifetime prevalence of PTSD in adults across the WHO World Mental Health Surveys3.9%Koenen et al., Posttraumatic stress disorder in the World Mental Health Surveys, Psychol Med 2017 · checkedPrevalence of psoriatic arthritis among adults112 per 100 000 adultsLembke et al., The worldwide prevalence of psoriatic arthritis: a systematic review and meta-analysis, Rheumatology (Oxford) 2024 · checkedPrevalence of chronic fatigue syndrome/ME (CDC-1994 case definition)0.89%Lim et al., Systematic review and meta-analysis of the prevalence of CFS/ME, J Transl Med 2020 · checkedPooled global prevalence of irritable bowel syndrome in adults11.2%Lovell and Ford, Global prevalence of and risk factors for IBS: a meta-analysis, Clin Gastroenterol Hepatol 2012 · checkedPrevalence of fibromyalgia in the general population, range across studiesbetween 0.2 and 6.6%Marques et al., Prevalence of fibromyalgia: literature review update, Rev Bras Reumatol 2017 · checkedAll types of Ehlers-Danlos syndrome combined, worldwideat least 1 in 5,000NIH MedlinePlus Genetics, Ehlers-Danlos syndrome (Frequency) · checkedHuntington's disease among people of European ancestry3 to 7 per 100,000NIH MedlinePlus Genetics, Huntington disease (Frequency) · checkedAmericans living with sickle cell disease100,000NIH MedlinePlus Genetics, Sickle cell disease (Frequency) · checkedPooled prevalence of Huntington's disease, studies 2010 to 20224.88 per 100,000Movement Disorders 2022, Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis · checkedMenopausal women worldwide, projected for 20301.2 billionNamazi et al., Social Determinants of Health in Menopause: An Integrative Review, Int J Womens Health 2019 · checkedHighest reported national prevalence of Crohn's disease (Germany)322 per 100 000Ng et al., Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century, Lancet 2017 · checkedHighest reported national prevalence of ulcerative colitis (Norway)505 per 100 000Ng et al., Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century, Lancet 2017 · checkedUS adults (20 and over) with a history of kidney stones, NHANES 2015-201610.1%Chewcharat and Curhan, Trends in the prevalence of kidney stones in the United States from 2007 to 2016, Urolithiasis 2021 · checkedIndividuals with gastro-oesophageal reflux disease (GORD) worldwide, pooled meta-analysis estimate1.03 billionNirwan et al., Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis, Sci Rep 2020 · checkedPooled prevalence of primary Sjögren's syndrome60.82 cases per 100 000 inhabitantsQin et al., Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis 2015 · checkedPooled prevalence of myasthenia gravis12.4 people ... per 100,000 populationSalari et al., Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis, J Transl Med 2021 · checkedPooled prevalence of osteoporosis across 86 studies, ages 15 to 10518.3Salari et al., The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis, J Orthop Surg Res 2021 · checkedPeople with heart failure worldwidemore than 64 millionSavarese et al., Global burden of heart failure: a comprehensive and updated review of epidemiology, Cardiovasc Res 2023 · checkedPooled global seroprevalence of celiac disease1.4%Singh et al., Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis, Clin Gastroenterol Hepatol 2018 · checkedAdults with persistent ADHD (childhood onset), worldwide, 2020139.84 millionSong et al., The prevalence of adult ADHD: a global systematic review and meta-analysis, J Glob Health 2021 · checkedAdults with symptomatic ADHD (any onset), worldwide, 2020366.33 millionSong et al., The prevalence of adult ADHD: a global systematic review and meta-analysis, J Glob Health 2021 · checkedPeople aged 40 to 80 with glaucoma worldwide, projected for 202076.0 millionTham et al., Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis, Ophthalmology 2014 · checkedPeople living with systemic lupus erythematosus, worldwide3.41 millionAnnals of the Rheumatic Diseases 2023, Global epidemiology of systemic lupus erythematosus (Tian et al.) · checkedPeople living with HIV worldwide in 202541.0 millionUNAIDS, Global HIV and AIDS statistics fact sheet (2026, data for 2025) · checkedRange of published narcolepsy prevalence estimatesfrom 1.05 to 79.40 per 100,000 populationWang et al., Heterogeneity in Estimates of Incidence and Prevalence of Narcolepsy: A Systematic Review and Meta-Regression Analysis, Neuroepidemiology 2022 · checkedPeople with an anxiety disorder worldwide, 2023470 millionWHO fact sheet, Anxiety disorders · checkedPeople affected by asthma worldwide, 2023363 millionWHO fact sheet, Asthma · checkedPeople living with bipolar disorder worldwide, 202336 millionWHO fact sheet, Bipolar disorder · checkedPeople living with dementia, worldwide (Alzheimer disease is the most common form)57 millionWHO fact sheet, Dementia · checkedPeople with depression worldwide, 2023322 millionWHO fact sheet, Depression · checkedPeople who experienced an eating disorder in 2023, worldwide18 millionWHO fact sheet, Mental disorders (11 September 2026), eating disorders section · checkedReproductive-age women with endometriosis worldwide190 million (10%)WHO fact sheet, Endometriosis · checkedPeople with epilepsy, worldwidearound 50 millionWHO fact sheet, Epilepsy · checkedPeople living with chronic hepatitis B infection worldwide in 2024240 millionWHO fact sheet, Hepatitis B (28 July 2026) · checkedPeople living with chronic hepatitis C virus infection worldwide47 millionWHO fact sheet, Hepatitis C (28 July 2026) · checkedAdults with hypertension worldwide, 20241.4 billionWHO fact sheet, Hypertension · checkedShare of the adult population experiencing infertility, worldwide17.5%WHO news release, 1 in 6 people globally affected by infertility · checkedPeople with low back pain, worldwide619 millionWHO fact sheet, Low back pain · checkedWomen aged 50 and over as a share of all women and girls worldwide, 202126%WHO fact sheet, Menopause · checkedPeople living with obesity, worldwide1.1 billionWHO fact sheet, Obesity and overweight · checkedPeople living with osteoarthritis, worldwideabout 528 millionWHO fact sheet, Osteoarthritis · checkedPeople with Parkinson disease, worldwideover 8.5 millionWHO fact sheet, Parkinson disease · checkedReproductive-aged women with PCOS worldwide10–13%WHO fact sheet, Polycystic ovary syndrome · checkedWomen who give birth affected by pre-eclampsia, worldwide3-8%WHO fact sheet, Pre-eclampsia · checkedPeople affected by psoriasis, worldwideapproximately 100 millionWHO news release, WHO publishes new report on psoriasis · checkedPeople living with rheumatoid arthritis, worldwide18 millionWHO fact sheet, Rheumatoid arthritis · checkedPeople living with sickle-cell disease, worldwide7.74 millionWHO fact sheet, Sickle-cell disease · checkedPeople living with schizophrenia, worldwide27 millionWHO fact sheet, Schizophrenia (11 September 2026) · checkedStroke cases worldwide, 202193.8 millionWHO fact sheet, Stroke · checkedPeople with age-related macular degeneration worldwide, projected for 2020196 millionWong et al., Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040, Lancet Glob Health 2014 · checkedGlobal prevalence of nonalcoholic fatty liver disease (NAFLD), pooled from population studies 1990 to 201930.05%Younossi et al., The global epidemiology of NAFLD and NASH: a systematic review, Hepatology 2023 · checkedGlobal seroprevalence of Borrelia burgdorferi antibodies14.5%BMJ Global Health 2022, Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis · checked
New diagnoses a year (79)
Deliveries affected by pre-eclampsia worldwide, modelled systematic review estimate4.6%Abalos et al., Global and regional estimates of preeclampsia and eclampsia: a systematic review, Eur J Obstet Gynecol Reprod Biol 2013 · checkedIncidence of recorded obstructive sleep apnoea in England, 201991.04 per 100,000Ali et al., Incidence, Characteristics, and Management Pathways of Obstructive Sleep Apnea in England: A 10-Year Retrospective Cohort Study (CHEST Pulmonary 2025), abstract · checkedCrude worldwide incidence of ALS1.59 per 100,000 person-yearsJournal of Neurology 2020, Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis · checkedIncidence of sarcoidosis, Sweden, 2003 to 201211.5 per 100 000 per yearArkema et al., Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden, Eur Respir J 2016 · checkedPooled incidence rate of multiple sclerosis across 75 reporting countries2.1 per 100,000 persons/yearMultiple Sclerosis Journal 2020, Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition · checkedIncidence of diagnosed CFS/ME in Norway, 2008 to 201225.8 per 100,000 person yearsBakken et al., Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008-2012 (BMC Medicine 2014), abstract · checkedPooled incidence of myasthenia gravis (all MG)5.3 per million person-yearsCarr et al., A systematic review of population based epidemiological studies in Myasthenia Gravis, BMC Neurol 2010 · checkedAnnual incidence of recorded fibromyalgia diagnoses in UK primary care, 2001 to 201333.3Collin et al., Trends in the incidence of chronic fatigue syndrome and fibromyalgia in the UK, 2001-2013: a Clinical Practice Research Datalink study (J R Soc Med 2017), abstract · checkedMedian incidence of physician-diagnosed IBS across 19 general population cohorts38.5 per 10 000 person-yearsCreed, Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies (Aliment Pharmacol Ther 2019), abstract · checkedIncidence of hypothyroidism in Europe226.2 per 100 000 per yearJournal of Clinical Endocrinology & Metabolism 2014, The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis · checkedIncident cases of ischaemic heart disease worldwide, 201710.6 millionGlobal Burden of Ischemic Heart Disease and Attributable Risk Factors, 1990-2017, Clin Epidemiol 2021 · checkedIncident cases of acne vulgaris, worldwide, 2019117·4 millionBritish Journal of Dermatology 2022, Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories (GBD 2019) · checkedNew cases of anxiety disorders worldwide, 201945.82 millionEpidemiology and Psychiatric Sciences 2021, Global, regional and national burden of anxiety disorders from 1990 to 2019 (GBD 2019) · checkedNew cases of hypertensive disorders of pregnancy worldwide, 201918.08 millionWang et al., Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels (GBD 2019), BMC Pregnancy Childbirth 2021 · checkedIncident cases of rheumatoid arthritis in 2019, worldwide1,074,390.80 casesClinical and Experimental Rheumatology 2023, Global, regional and national burden of rheumatoid arthritis 1990 to 2019 (GBD 2019) · checkedNew cases of atrial fibrillation/flutter worldwide, 20214.48 millionGlobal burden and health inequality of atrial fibrillation/atrial flutter from 1990 to 2021 (GBD 2021) · checkedNew cases of atopic dermatitis worldwide, 202116.0 millionJournal of Allergy and Clinical Immunology: Global 2025, Global trends and modifiable risk factors for atopic dermatitis incidence: Insights from GBD 2021 · checkedNew cases of bipolar disorder among people aged 15 to 49 worldwide, 20211.63 millionHealth Science Reports 2026, Comparative Analysis of the Burden of Bipolar Disorder Among Individuals Aged 15-49 Years in China and Globally, 1990-2021 (GBD 2021) · checkedNew cases of chronic kidney disease worldwide, 202119,935,038BMC Nephrology 2025, Global trends of chronic kidney disease from 1990 to 2021: a systematic analysis for the global burden of disease study 2021 · checkedNew cases of COPD worldwide, 202116.90 millionBMC Medicine 2025, Mapping the Global distribution, risk factors, and temporal trends of COPD incidence and mortality (1990-2021): ecological analysis · checkedNew cases of depressive disorders worldwide, 2021357.44 millionBritish Journal of Psychiatry 2025, Global, regional and national burden of depressive disorders and attributable risk factors, from 1990 to 2021 (GBD 2021) · checkedAge-standardised incidence rate of eating disorders (anorexia and bulimia nervosa) worldwide, 2021124.4 per 100,000Liu et al., Global, regional, and national burdens of eating disorders from 1990 to 2021 and projection to 2035, Front Nutr 2025 · checkedNew (incident) cases of GERD worldwide, 2021324.1 millionDong et al., Global burden of gastroesophageal reflux disease, 1990-2021, with projections to 2040 (GBD 2021), Dis Esophagus 2025 · checkedNew cases of inflammatory bowel disease (Crohn's disease and ulcerative colitis together) worldwide, 2021375140International Journal of Colorectal Disease 2024, Global, regional, and national burden of inflammatory bowel disease, 1990-2021 (GBD 2021) · checkedIncident cases of migraine worldwide, 202190.18 millionThe global and regional burden and trends of migraine from 1990 to 2021: Global Burden of Disease Study 2021 · checkedNew (incident) cases of NAFLD worldwide in 202148.35 millionMao et al., Global burden of NAFLD 1990-2021 and projections to 2035: Results from the GBD study 2021, PLoS One 2025 · checkedAge-standardised incidence rate of osteoarthritis, worldwide, 2021535.0BMC Musculoskeletal Disorders 2024, Global, regional and national burden of osteoarthritis in 1990-2021 (GBD 2021) · checkedNew cases of polycystic ovary syndrome among women aged 15 to 49 worldwide, 20211,175.07 thousandFrontiers in Public Health 2025, Global burden of polycystic ovary syndrome among women of childbearing age, 1990-2021 (GBD 2021) · checkedAge-standardised incidence rate of psoriasis, worldwide, 202162 per 100,000Health Science Reports 2026, The Global Burden and Temporal Trends of Psoriasis, 1990-2021 · checkedPeople worldwide with a new (incident) episode of schizophrenia in 2021approximately 1.2 millionGBD 2021 Schizophrenia Collaborators, The Global Burden of Schizophrenia: Findings from the 2021 GBD Study, Schizophr Bull Open 2026 · checkedNew (incident) cases of urolithiasis (kidney and urinary stones) worldwide, 2021106 millionGBD 2021 Urolithiasis Collaborators, The global, regional, and national burden of urolithiasis in 204 countries and territories, 2000-2021, EClinicalMedicine 2024 · checkedNew cases of Hodgkin lymphoma worldwide, 202484 495IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedNew cases of leukaemia worldwide, 2024495 113IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedNew cases of lymphoma (Hodgkin and non-Hodgkin together) worldwide, 202484 495 ... 562 793IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer siteNew cases of melanoma of the skin worldwide, 2024337 969IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedNew cases of non-Hodgkin lymphoma worldwide, 2024562 793IARC Global Cancer Observatory, GLOBOCAN 2024 World fact sheet, table Incidence, Mortality and Prevalence by cancer site · checkedNew thyroid cancer cases worldwide, GLOBOCAN 2024959 281IARC Global Cancer Observatory, GLOBOCAN 2024 fact sheet: Thyroid · checkedPooled global incidence of idiopathic pulmonary fibrosis (IPF)5.8Golchin et al., Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis, BMC Pulm Med 2025 · checkedNew cases of type 1 diabetes diagnosed worldwide, 20210·5 millionGregory et al., Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040, Lancet Diabetes Endocrinol 2022 · checkedNew cases of type 2 diabetes worldwide, 202123.9 millionHuang et al., Global burden and risk factors of type 2 diabetes mellitus from 1990 to 2021, with forecasts to 2050 (Frontiers in Endocrinology 2025), abstract · checkedNew diagnoses of cystic fibrosis in Italy, 2024134 in 2024Italian Cystic Fibrosis Registry (ICFR), Report 2023-2024 (Epidemiologia e Prevenzione 2026), abstract · checkedLive births affected by hyperglycaemia in pregnancy each year, worldwide (IDF Diabetes Atlas 2025)23 millionIDF Diabetes Atlas 11th edition (2025), Frequently asked questionsPooled incidence of any tinnitus1164 per 100 000 person-yearsJarach et al., Global Prevalence and Incidence of Tinnitus: A Systematic Review and Meta-analysis, JAMA Neurol 2022 · checkedNew gout cases worldwide, 20219.4 million new casesJin et al., Global burden and trends of gout incidence and prevalence, Chin Med J 2025 (GBD 2021 secondary analysis) · checkedPooled incidence of celiac disease in adults, 21st century12.9American Journal of Gastroenterology 2020, Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis · checkedPooled incidence of celiac disease in children, 21st century21.3 per 100,000 person-yearsAmerican Journal of Gastroenterology 2020, Incidence of Celiac Disease Is Increasing Over Time: A Systematic Review and Meta-analysis · checkedNew incident cases of low back pain worldwide, 2021266.9 millionLi et al., Global burden of low back pain and its attributable risk factors from 1990 to 2021: GBD 2021 (Frontiers in Public Health 2024), abstract · checkedPeople treated for Lyme disease each year, US (insurance claims estimate)476,000CDC, Lyme disease data and statistics · checkedIncident cases of asthma worldwide, 202137.86 millionMao et al., Global, regional, and national burden of asthma from 1990 to 2021: GBD 2021 (Chinese Medical Journal Pulmonary and Critical Care Medicine 2025), results · checkedPooled incidence of Huntington's disease, studies 2010 to 20220.48 cases per 100,000 person-yearsMovement Disorders 2022, Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis · checkedIncidence of chronic pain among pain-free US adults, 2019 to 202052.4Nahin et al., Estimated Rates of Incident and Persistent Chronic Pain Among US Adults, 2019-2020, JAMA Netw Open 2023 · checkedIncidence of obesity among US adults without obesity, 2001 to 201728.1/1000 PYsNielsen et al., Incidence of obesity across adulthood in the United States, 2001-2017: a national prospective analysis (Am J Clin Nutr 2023), abstract · checkedAnnual incidence of obstructive sleep apnoea treated in secondary care, Helsinki and Uusimaa hospital district, 2019564 per 100 000Peuranheimo et al., Increasing incidence and burden of obstructive sleep apnoea in the Finnish population: a cohort study from 2005 to 2019 (Respiratory Medicine 2025), abstract · checkedPeople diagnosed with Parkinson's disease each year, USnearly an estimated 90,000Parkinson's Foundation, Parkinson's statistics · checkedPooled incidence of primary Sjögren's syndrome6.92 per 100 000 person-yearsQin et al., Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis 2015 · checkedAdults newly diagnosed with hypertension in Canada, 2007/08about 418,000Robitaille et al., Diagnosed hypertension in Canada: incidence, prevalence and associated mortality (CMAJ 2011), abstract · checkedPooled incidence of psoriatic arthritis in population-based studies83 every 100,000 PYScotti et al., Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis, Semin Arthritis Rheum 2018 · checkedMedian annual incidence of heart failure in ESC member countries reporting it3.20 casesShahim et al., Global Public Health Burden of Heart Failure: An Updated Review (Cardiac Failure Review 2023), Incidence section · checkedIncidence of heart failure in European countries and the USone to nine cases per 1,000 person-yearsShahim et al., Global Public Health Burden of Heart Failure: An Updated Review (Cardiac Failure Review 2023), Incidence section · checkedIncidence of primary open-angle glaucoma, ages 40 to 79, 202223.46 per 10 000 person-yearsShan et al., Global incidence and risk factors for glaucoma: a systematic review and meta-analysis of prospective studies, J Glob Health 2024 · checkedAge-standardised incidence of ADHD worldwide, 202158.67 per 100,000Frontiers in Psychiatry 2025, Comparative analysis of Attention Deficit Hyperactivity Disorder in China and worldwide based on the Global Burden of Disease study · checkedNewly diagnosed people with systemic lupus erythematosus each year, worldwide0.40 millionAnnals of the Rheumatic Diseases 2023, Global epidemiology of systemic lupus erythematosus (Tian et al.) · checkedPeople who newly acquired HIV worldwide in 20251.2 millionUNAIDS, Global HIV and AIDS statistics fact sheet (2026, data for 2025) · checkedPooled annual incidence of early age-related macular degeneration1.59 ... per 100 person-yearsWang et al., Global Incidence, Progression, and Risk Factors of Age-Related Macular Degeneration and Projection of Disease Statistics in 30 Years: A Modeling Study, Gerontology 2022 · checkedRange of published narcolepsy incidence estimatesfrom 0.06 to 6.56 per 100,000 person-yearsWang et al., Heterogeneity in Estimates of Incidence and Prevalence of Narcolepsy: A Systematic Review and Meta-Regression Analysis, Neuroepidemiology 2022 · checkedNew cases of prostate cancer in a year, worldwide1,467,854World Cancer Research Fund, Prostate cancer statistics (GLOBOCAN 2022) · checkedWomen diagnosed with breast cancer in a year, worldwide2.4 millionWHO fact sheet, Breast cancer · checkedNew cases of colorectal cancer in a year, worldwide1.9 millionWHO fact sheet, Colorectal cancer · checkedNew dementia cases each year, worldwide (Alzheimer disease is the most common form)nearly 10 millionWHO fact sheet, Dementia · checkedPeople diagnosed with epilepsy each year, worldwidean estimated 5 millionWHO fact sheet, Epilepsy · checkedNew hepatitis B infections worldwide each year0.9 millionWHO fact sheet, Hepatitis B (28 July 2026) · checkedNew hepatitis C virus infections worldwide each yearabout 0.9 millionWHO fact sheet, Hepatitis C (28 July 2026) · checkedShare of people with COVID-19 who develop post COVID-19 condition (long COVID)6 in every 100WHO fact sheet, Post COVID-19 condition (long COVID) · checkedNew cases of lung cancer in a year, worldwide2.5 millionWHO fact sheet, Lung cancer · checkedBabies born with sickle-cell disease in a year, worldwide515 000 new birthsWHO fact sheet, Sickle-cell disease · checkedNew cases of stroke worldwide, 202111.9 millionWHO fact sheet, Stroke · checkedAge- and sex-adjusted incidence of ankylosing spondylitis in adults, Olmsted County, Minnesota, 1980 to 20093.1 per 100,000Wright et al., Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study, Arthritis Care Res 2015 · checkedWomen worldwide entering the menopause transition each yearmore than 47 millionWright et al., The musculoskeletal syndrome of menopause, Climacteric 2024 · checkedNew cases of endometriosis worldwide, 20213,447,126Yu et al., Global burden of endometriosis from 1990 to 2021 and projections to 2050: GBD 2021 (Frontiers in Global Women's Health 2025), abstract · checked
Records patients typically hold (305)
Direct-acting antiviral course (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir)8 weeks of glecaprevir/pibrentasvir or 12 weeks of sofosbuvir/velpatasvirAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checkedLiver ultrasound surveillance for liver cancer after treatment, in cirrhosisevery 6 monthsAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checkedQuantitative HCV RNA (with HIV and HBsAg tests) before treatmentany time prior to initiating DAA therapyAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checkedHCV RNA and aminotransferase test to confirm cure (SVR)12 or more weeks after completing DAA treatmentAASLD-IDSA, Hepatitis C Guidance 2019 Update, Hepatology 2020 (simplified treatment algorithm) · checkedActigraphy for 2 weeks before testingfor 2 weeks before testingKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021Multiple Sleep Latency Test (MSLT) report5 nap trialsKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021Overnight facility-based polysomnography before the MSLTthe night before the MSLTKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021Sleep diary for 2 weeks before testingfor 2 weeks before testingKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021Urine drug screen on the MSLT daywhen indicatedKrahn et al., Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine, J Clin Sleep Med 2021Baseline electrocardiogram (ECG)baseline ECGCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checkedEBUS-guided lymph node sampling (tissue for histology)EBUS-guided lymph node samplingCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checkedBaseline eye examinationa baseline eye examinationCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checkedBaseline serum calcium testbaseline serum calcium testingCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checkedBaseline serum creatinine testbaseline serum creatinine testingCrouser et al., Diagnosis and Detection of Sarcoidosis: An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 2020 · checkedBlood count monitoring for recurrent IDAperhaps every 6 months initiallySnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checkedCoeliac disease screening and urinalysisinitial investigation of confirmed IDASnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checkedGastroscopy and colonoscopy (bidirectional endoscopy)first-line GI investigationsSnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checkedHaemoglobin check for response to oral ironin the first 4 weeksSnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checkedSerum ferritin blood testthe single most useful marker of IDASnook et al., British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults, Gut 2021 · checkedBaseline blood tests for associated conditions (thyroid, liver, TTG, immunoglobulins, vitamin D and others)at baseline, and repeated as clinically indicatedBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checkedHydroxychloroquine prescription6–12 monthsBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checkedMinor labial salivary gland biopsyminor labial salivary gland biopsyBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checkedSalivary gland ultrasoundUSS of the salivary glandsBritish Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease, executive summary, Rheumatology (Oxford) 2025 · checkedPrescription drug monitoring program (PDMP) review of controlled-substance prescriptionsevery 3 months or more frequentlyDowell et al., CDC Clinical Practice Guideline for Prescribing Opioids for Pain: United States, 2022, MMWR Recomm Rep 2022, Recommendation 9 · checkedPEG pain and function questionnaire (3 items) at reassessmentevery 3 months or more frequentlyDowell et al., CDC Clinical Practice Guideline for Prescribing Opioids for Pain: United States, 2022, MMWR Recomm Rep 2022, Recommendation 7 · checkedUrine toxicology testat least annuallyDowell et al., CDC Clinical Practice Guideline for Prescribing Opioids for Pain: United States, 2022, MMWR Recomm Rep 2022, Recommendation 10 · checked24-hour urine collection (metabolic evaluation)every twelve monthsEAU Guidelines on Urolithiasis (2026 edition), Metabolic Evaluation and Recurrence Prevention · checkedBlood count and physical examination while early-stage chronic lymphocytic leukaemia is watched3- to 12-monthly controls by blood countEichhorst and Ghia, EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia (HemaSphere 2020) · checkedComplete blood count and thyroid function testsfor selected patients2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checked12-lead ECG with orthostatic vital signs at POTS assessmentshould be performed on patients being assessed for POTS2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checkedTransthoracic echocardiogram (with tilt-table or autonomic testing in selected patients)may be considered for selected patients being assessed for POTS2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checked24-hour Holter monitor (ambulatory ECG)may be considered for selected patients being assessed for POTS2015 Heart Rhythm Society expert consensus statement on POTS, IST and vasovagal syncope, recommendations on investigation of POTS · checkedAnti-acetylcholine receptor (AChR) antibody blood testAnti-AChR antibody testingShelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checkedMG-ADL patient-reported scaleMG-ADLShelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checkedBlood count and liver function monitoring on azathioprineregular monitoringShelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checkedChest CT or MRI for thymomachest computed tomography (CT) or magnetic resonance imaging (MRI)Shelly et al., National guidelines for diagnosis, treatment, and management of myasthenia gravis in Israel, Ther Adv Neurol Disord 2025 · checkedFour-Dimensional Symptom Questionnaire (4DKL) to support the diagnosis of work strain and burnout4DKLMultidisciplinaire richtlijn overspanning en burnout voor eerstelijns professionals (LVE, NHG and NVAB, the Dutch occupational physicians' association, 2011), section 4.3 Aanbevelingen · checkedPhysical examination and additional tests (such as blood tests) for burnout: not indicatedNiet geïndiceerdNHG-Standaard Overspanning en burn-out (Dutch College of General Practitioners), as published in Huisarts en Wetenschap, November 2018, Richtlijnen diagnostiek · checkedSurveillance colonoscopyevery 5 years (low risk), 3 years (intermediate risk), 1 year (high risk)NICE CG118, Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas · checkedBaseline colonoscopy with targeted biopsyonce, to set the surveillance riskNICE CG118, Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas · checkedSurveillance colonoscopyevery 5 years (low risk), 3 years (intermediate risk), 1 year (high risk)NICE CG118, Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn's disease or adenomas · checkedWritten report of the autism diagnostic assessment (children and young people), shared with the GPa written report of the autism diagnostic assessmentNICE CG128, Autism spectrum disorder in under 19s: recognition, referral and diagnosis, recommendations 1.8.4 and 1.8.5 · checkedAntipsychotic prescription for behaviour that challenges, with an early reviewafter 3–4 weeksNICE CG142, Autism spectrum disorder in adults: diagnosis and management, recommendation 1.5.7 · checkedAutism-Spectrum Quotient 10-item questionnaire (AQ-10) for adults with possible autismscores 6 or above on the AQ-10NICE CG142, Autism spectrum disorder in adults: diagnosis and management, recommendation 1.2.3 · checkedCare plan based on the comprehensive autism assessment (adults)Develop a care plan based on the comprehensive assessmentNICE CG142, Autism spectrum disorder in adults: diagnosis and management, recommendation 1.2.13 · checkedHeadache diary for menstrual-related migrainefor at least 2 menstrual cyclesNICE CG150, Headaches in over 12s: diagnosis and management, section 1.1 · checkedHeadache diary to monitor treatmentongoing, to monitor treatmentNICE CG150, Headaches in over 12s: diagnosis and management, section 1.3 · checkedBrain imaging for migraine: only when warning features develop, never solely for reassuranceneuroimaging solely for reassuranceNICE CG150, Headaches in over 12s: diagnosis and management, recommendations 1.3.2 and 1.3.3 · checkedReview of migraine preventive medication after it is started3 to 6 months after starting prophylactic treatmentNICE CG150, Headaches in over 12s: diagnosis and management, recommendation 1.3.27 · checkedSpecialist follow-up reviewevery 3 months ... every 6 months ... annuallyNICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.6 Review and follow-up · checkedCT of the thorax with high-resolution imagesperforming CT of the thorax (including high-resolution images)NICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.2 Diagnosis · checkedBronchoalveolar lavage, transbronchial biopsy or surgical lung biopsyconsider ... surgical lung biopsyNICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.2 Diagnosis · checkedLung function tests (spirometry and gas transfer)diagnosis and 6 months and 12 months after diagnosisNICE CG163, Idiopathic pulmonary fibrosis in adults: diagnosis and management, section 1.4 Prognosis · checkedHBV DNA, quantitative HBsAg and HBeAg status on tenofovirthen every 6 monthsNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.6.16 · checkedAnnual transient elastography (liver stiffness scan) for adults not on antiviral treatmentan annual reassessment of liver disease using transient elastographyNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.3.8 · checkedLiver ultrasound and alpha-fetoprotein surveillance for liver cancer6-monthlyNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.7.1 · checkedFull blood count, liver and renal function, and phosphate on tenofovirthen every 3 monthsNICE CG165, Hepatitis B (chronic): diagnosis and management, recommendation 1.6.15 · checkedBaseline bloods before antipsychotics: glucose or HbA1c, lipid profile and prolactinBefore starting antipsychotic medicationNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.3.6.1 · checkedClozapine prescription for treatment-resistant schizophreniaat least 2 different antipsychotic drugsNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.5.7.2 · checkedECG before antipsychotic medication (when indicated)Before starting antipsychotic medicationNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.3.6.2 · checkedFasting blood glucose or HbA1c, and blood lipids, on antipsychotic medicationat 12 weeks, at 1 year and then annuallyNICE CG178, Psychosis and schizophrenia in adults: prevention and management, recommendation 1.3.6.4 · checkedAnnual review of long-term reflux and dyspepsia medicationan annual reviewNICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, section 1.5 Reviewing patient care · checkedUpper GI endoscopy (with histopathology) to diagnose Barrett's oesophagusconsider it if the person has GORDNICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, section 1.6.11 · checkedHelicobacter pylori test (carbon-13 urea breath test or stool antigen test)'test and treat'NICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, sections 1.4 and 1.6 · checkedFull-dose proton pump inhibitor (PPI) coursefor 4 or 8 weeksNICE CG184, Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, section 1.6 Interventions for GORD · checkedECG and blood pressure before clomipraminebefore prescribing clomipramineNICE CG31, Obsessive-compulsive disorder and body dysmorphic disorder: treatment, recommendation 1.5.4.12 · checkedSSRI prescription, reviewed after 12 months of remission12 months after remissionNICE CG31, Obsessive-compulsive disorder and body dysmorphic disorder: treatment, recommendation 1.5.3.16 · checkedWritten agreement on who monitors and treats the patient, copy given to the patientA written copy of this agreement should be given to the patientNICE CG31, Obsessive-compulsive disorder and body dysmorphic disorder: treatment, coordination of care · checkedAnnual RA reviewannuallyNICE NG100, Rheumatoid arthritis in adults: management, section 1.8 · checkedCRP blood test and DAS28 disease activity scoremonthly in specialist care until remission or low disease activityNICE NG100, Rheumatoid arthritis in adults: management, section 1.4 · checkedRheumatoid factor blood testat diagnosisNICE NG100, Rheumatoid arthritis in adults: management, section 1.1 · checkedX-ray of hands and feetat diagnosisNICE NG100, Rheumatoid arthritis in adults: management, section 1.1 · checkedTransthoracic echocardiogramat diagnosisNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.2 · checkedNT-proBNP blood testat suspected diagnosisNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.2 · checkedKidney function and electrolytes blood testevery 3 to 6 months once the maximum tolerated dose has been establishedNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.7 · checkedHeart failure care review in primary careat least every 6 monthsNICE NG106, Chronic heart failure in adults: diagnosis and management, section 1.1 · checkedCOPD reviewat least once per year, more often if indicatedNICE NG115, Chronic obstructive pulmonary disease in over 16s, follow-up · checkedAnnual flu vaccination and pneumococcal vaccinationannual flu vaccinationNICE NG115, Chronic obstructive pulmonary disease in over 16s, managing stable COPD · checkedLong-term oxygen therapy review with pulse oximetryat least once per yearNICE NG115, Chronic obstructive pulmonary disease in over 16s, oxygen · checkedReview for very severe COPDat least twice per yearNICE NG115, Chronic obstructive pulmonary disease in over 16s, follow-up · checkedCare plan agreed with the new service at each transition of carebefore a care plan has been agreed in the new serviceNICE NG116, Post-traumatic stress disorder, recommendation 1.2.5 · checkedVenlafaxine or SSRI (such as sertraline) prescription for adults with PTSDReview this treatment regularlyNICE NG116, Post-traumatic stress disorder, recommendation 1.6.25 · checkedValidated brief PTSD screening questionnaire after a major disasterat 1 month after the disasterNICE NG116, Post-traumatic stress disorder, recommendation 1.1.7 · checkedLow-dose non-contrast CT for suspected renal colicwithin 24 hours of presentationNICE NG118, Renal and ureteric stones: assessment and management, section 1.1 Diagnostic imaging · checkedSerum calcium blood testmeasure serum calciumNICE NG118, Renal and ureteric stones: assessment and management, section 1.7 Metabolic testing · checkedStone composition analysisconsider stone analysisNICE NG118, Renal and ureteric stones: assessment and management, section 1.7 Metabolic testing · checkedVery urgent full blood count when leukaemia is suspected in an adultvery urgent full blood countNICE NG12, Suspected cancer: recognition and referral, recommendation 1.10.1 · checkedReview of infliximab or adalimumab treatmentat least every 12 monthsNICE NG129, Crohn's disease: management, section 1.2 · checkedBlood monitoring for azathioprine, mercaptopurine or methotrexateas advised in the BNFNICE NG129, Crohn's disease: management, section 1.2 · checkedReview of biologic or JAK inhibitor treatmentat least every 12 monthsNICE NG130, Ulcerative colitis: management, section 1.2 · checkedFull blood count, liver function and renal function blood teststwice a weekNICE NG133, Hypertension in pregnancy: diagnosis and management, table 2 Management of pregnancy with pre-eclampsia · checkedUltrasound assessment of the fetus (growth, amniotic fluid, umbilical artery doppler)at diagnosis and, if normal, repeat every 2 weeksNICE NG133, Hypertension in pregnancy: diagnosis and management, table 2 Management of pregnancy with pre-eclampsia · checkedPlacental growth factor (PLGF)-based testbetween 20 weeks and 36 weeks and 6 days of pregnancyNICE NG133, Hypertension in pregnancy: diagnosis and management, section 1.4 Gestational hypertension · checkedUrinary reagent-strip (protein) test after the birth6 to 8 weeks after the birthNICE NG133, Hypertension in pregnancy: diagnosis and management, section 1.5 Pre-eclampsia, postnatal care · checkedAmbulatory blood pressure monitoring (ABPM)at diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.2 · checkedBlood tests at diagnosis (HbA1c, electrolytes, creatinine, eGFR, cholesterol)at diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.3 · checked12-lead ECGat diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.3 · checkedUrine albumin to creatinine ratioat diagnosisNICE NG136, Hypertension in adults: diagnosis and management, section 1.3 · checkedBlood pressure measurementat least annuallyNICE NG136, Hypertension in adults: diagnosis and management, section 1.2 · checkedBRAF analysis of the melanoma tissue samplestage IIB to IV primary melanomaNICE NG14, Melanoma: assessment and management, recommendation 1.3.10 · checkedSentinel lymph node biopsy (histopathology) for staging melanomaBreslow thickness greater than 1.0 mmNICE NG14, Melanoma: assessment and management, recommendation 1.4.4 · checkedWhole-body and brain contrast-enhanced CT during follow-up of stage IIC melanoma2 whole-body and brain CE CT scans each yearNICE NG14, Melanoma: assessment and management, table Follow-up after stages I to IV melanoma · checkedThyroid peroxidase antibodies (TPOAb)once (do not repeat)NICE NG145, Thyroid disease: assessment and management, section 1.2 · checkedTSH blood test for diagnosisat diagnosisNICE NG145, Thyroid disease: assessment and management, section 1.2 · checkedTSH blood test on levothyroxineevery 3 months until stable, then once a yearNICE NG145, Thyroid disease: assessment and management, section 1.3 · checkedAudiological assessment (hearing test)audiological assessmentNICE NG155, Tinnitus: assessment and management, recommendations · checkedInsomnia Severity Index questionnaireInsomnia Severity IndexNICE NG155, Tinnitus: assessment and management, recommendations · checkedMRI of the internal auditory meatiMRI (IAM)NICE NG155, Tinnitus: assessment and management, recommendations · checkedTinnitus Functional Index questionnaireTinnitus Functional IndexNICE NG155, Tinnitus: assessment and management, recommendations · checkedAnnual review of self-care and needsannuallyNICE NG17, Type 1 diabetes in adults: diagnosis and management · checkedContinuous glucose monitoring (real-time or flash)a choice of real-time continuous glucose monitoring (rtCGM) or intermittently scanned continuous glucose monitoringNICE NG17, Type 1 diabetes in adults: diagnosis and management, recommendation 1.6.10Kidney tests (eGFR and urine albumin:creatinine ratio)annually, with cardiovascular risk assessmentNICE NG17, Type 1 diabetes in adults: diagnosis and management · checkedHbA1c testevery 3 to 6 monthsNICE NG17, Type 1 diabetes in adults: diagnosis and management · checkedLeft ventricular function assessment (echocardiogram)after a heart attack (STEMI)NICE NG185, Acute coronary syndromes, STEMI · checkedBlood tests (full blood count, kidney and liver function, CRP, ferritin, BNP, HbA1c, thyroid)when clinically indicatedNICE NG188, COVID-19 rapid guideline: managing the long-term effects of COVID-19, section 3 · checkedChest X-rayonce, by 12 weeks after acute COVID-19, if respiratory symptoms continueNICE NG188, COVID-19 rapid guideline: managing the long-term effects of COVID-19, section 3 · checkedHome self-monitoring (heart rate, blood pressure, pulse oximetry, symptom diary)supported self-monitoring at home, as agreedNICE NG188, COVID-19 rapid guideline: managing the long-term effects of COVID-19, section 3 · checkedAnnual foot examination (diabetic foot risk check)annually for people at low risk, as part of the annual diabetes reviewNICE NG19, Diabetic foot problems: prevention and management · checkedAntidepressant prescription for chronic primary painfor people aged 18 years and overNICE NG193, Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain, section 1.2 Managing chronic primary pain · checkedCare and support plan from a person-centred pain assessmentreview the care and support planNICE NG193, Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain, section 1.1 · checkedAmbulatory ECG monitorwhen paroxysmal AF is suspectedNICE NG196, Atrial fibrillation: diagnosis and management, section 1.1 · checkedAnticoagulation reviewat least annuallyNICE NG196, Atrial fibrillation: diagnosis and management, section 1.7 · checked12-lead ECGat diagnosisNICE NG196, Atrial fibrillation: diagnosis and management, section 1.1 · checkedTransthoracic echocardiogrambaseline, and before rhythm controlNICE NG196, Atrial fibrillation: diagnosis and management, section 1.7 · checkedAnnual coeliac reviewannuallyNICE NG20, Coeliac disease: recognition, assessment and management, section 1.4 · checkedEndoscopic intestinal biopsyat diagnosisNICE NG20, Coeliac disease: recognition, assessment and management, section 1.1 · checkedIgA tissue transglutaminase (tTG) antibody blood testat diagnosisNICE NG20, Coeliac disease: recognition, assessment and management, section 1.1 · checkedUrine albumin:creatinine ratio (ACR)individualised by risk of progressionNICE NG203, Chronic kidney disease: assessment and management, section 1.1 · checkedeGFR blood testminimum number of checks per year depends on GFR and ACR categoryNICE NG203, Chronic kidney disease: assessment and management, table 2 · checkedGFR monitoring for people on kidney-affecting medicinesat least annuallyNICE NG203, Chronic kidney disease: assessment and management, section 1.1 · checked12-lead ECG after a first seizureafter a first suspected seizureNICE NG217, Epilepsies in children, young people and adults, section 1 · checkedEEG (electroencephalogram)at diagnosisNICE NG217, Epilepsies in children, young people and adults, section 1 · checkedEpilepsy monitoring reviewregular (at least annual)NICE NG217, Epilepsies in children, young people and adults, section 4.4 Monitoring and review · checkedMRI of the brainat diagnosisNICE NG217, Epilepsies in children, young people and adults, section 1 · checkedJoint aspiration and synovial fluid microscopyif a diagnosis of gout remains uncertain or unconfirmedNICE NG219, Gout: diagnosis and management, recommendations · checkedX-ray, ultrasound or dual-energy CT of affected jointsX-ray, ultrasound or dual-energy CTNICE NG219, Gout: diagnosis and management, recommendations · checkedAnnual serum urate monitoring on urate-lowering therapyannualNICE NG219, Gout: diagnosis and management, recommendations · checkedSerum urate blood test to confirm the diagnosisto confirm the clinical diagnosisNICE NG219, Gout: diagnosis and management, recommendations · checkedSerum urate blood tests while urate-lowering therapy is titratedmonthlyNICE NG219, Gout: diagnosis and management, recommendations · checkedComprehensive MS care reviewat least once a yearNICE NG220, Multiple sclerosis in adults: management, comprehensive review · checkedMRI of the brain and spinal cordat diagnosisNICE NG220, Multiple sclerosis in adults: management, diagnosis · checkedReview of spasticity medicinesat least annually once the optimal dose has been reachedNICE NG220, Multiple sclerosis in adults: management, spasticity · checkedSerum FSH blood test to confirm menopauseonly in people aged 40 to 45NICE NG23, Menopause: identification and management, section 1.3 Identifying perimenopause and menopause · checkedReview of each menopause treatment (HRT and other treatments)at 3 months ... annually thereafterNICE NG23, Menopause: identification and management, section 1.9 Reviewing treatment for anyone · checkedTwo FSH blood tests to diagnose premature ovarian insufficiency (under 40)2 blood samples taken 4 to 6 weeks apartNICE NG23, Menopause: identification and management, section 1.7 Diagnosing and managing premature ovarian insufficiency · checkedNeck ultrasound after surgery without radioactive iodineat 6 to 12 months initiallyNICE NG230, Thyroid cancer: assessment and management, section 1.6 Follow-up of differentiated thyroid cancer · checkedThyroglobulin and thyroglobulin antibody blood tests3- to 6-month intervals in the first 2 years ... 6- to 12-month intervals thereafterNICE NG230, Thyroid cancer: assessment and management, section 1.5 Post-thyroidectomy monitoring · checkedFine-needle aspiration cytology (FNAC)offer fine-needle aspiration cytologyNICE NG230, Thyroid cancer: assessment and management, section 1.2 · checkedThyroid ultrasound with graded appearancethe initial diagnostic testNICE NG230, Thyroid cancer: assessment and management, section 1.2 · checkedThyroid hormone (levothyroxine) prescription at TSH-suppressing doseuntil follow-up review at 9 to 12 monthsNICE NG230, Thyroid cancer: assessment and management, section 1.4 TSH suppression · checkedFull lipid profileannuallyNICE NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification, annual medication review · checkedAnnual medication review (lipid-lowering treatment)annuallyNICE NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification, annual medication review · checkedAsthma control questionnaire (ACQ or ACT)at any asthma reviewNICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, monitoring · checkedBlood eosinophil count or FeNO testat diagnosis (repeat as clinically needed)NICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, objective tests for adults · checkedSpirometry with bronchodilator reversibilityat diagnosis (repeat as clinically needed)NICE NG245, Asthma: diagnosis, monitoring and chronic asthma management, objective tests for adults · checkedBaseline DXA bone density scan when starting treatmentbaselineNICE NG259, Osteoporosis: risk assessment, fragility fracture risk assessment · checkedDXA-based vertebral fracture assessment (VFA)when doing a DXA scanNICE NG259, Osteoporosis: risk assessment, identifying vertebral fragility fractures · checkedDiabetic eye screening (retinal photographs)at diagnosis, then through the national screening serviceNICE NG28, Type 2 diabetes in adults: management, section 1.43 Eye disease · checkedHbA1c testevery 3 to 6 months until stable, then every 6 monthsNICE NG28, Type 2 diabetes in adults: management, section 1.5 HbA1c measurement and targets · checkedUltrasound monitoring of fetal growth and amniotic fluid volumeevery 4 weeks from 28 to 36 weeksNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.4 Antenatal care · checkedAnnual HbA1c test after gestational diabetesan annual HbA1c testNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.6 Postnatal care · checkedHome capillary blood glucose readings (fasting and 1-hour post-meal)dailyNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.3 Blood glucose monitoring · checked75-g 2-hour oral glucose tolerance test (OGTT)at 24 to 28 weeksNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.2 Gestational diabetes · checkedPostnatal fasting plasma glucose test6 to 13 weeks after the birthNICE NG3, Diabetes in pregnancy: management from preconception to the postnatal period, section 1.6 Postnatal care · checkedIntegrated diagnostic report from a specialist haematological malignancy diagnostic service (SIHMDS)all new diagnosesNICE NG47, Haematological cancers: improving outcomes, recommendation 1.3.17 · checkedLiver ultrasound to diagnose MASLD in children and young peopleOffer a liver ultrasound to test children and young people for MASLDNICE NG49, MASLD: assessment and management, recommendation 1.2.1 · checkedRepeat ELF test for people with an ELF score below 10.51every 3 years to adults every 2 years to children and young peopleNICE NG49, MASLD: assessment and management, recommendation 1.3.7 · checkedEnhanced liver fibrosis (ELF) blood test after MASLD diagnosisConsider using the enhanced liver fibrosis (ELF) testNICE NG49, MASLD: assessment and management, recommendation 1.3.2 · checkedFDG-PET-CT scan at the end of treatment for diffuse large B-cell or Burkitt lymphomaat completion of planned treatmentNICE NG52, Non-Hodgkin's lymphoma: diagnosis and management, recommendation 1.2.4 · checkedExcision biopsy (histopathology) to diagnose non-Hodgkin lymphomaexcision biopsy as the first diagnostic procedureNICE NG52, Non-Hodgkin's lymphoma: diagnosis and management, recommendation 1.1.1 · checkedFISH test of the lymphoma for an MYC rearrangement in high-grade B-cell lymphomaMYC rearrangementNICE NG52, Non-Hodgkin's lymphoma: diagnosis and management, recommendation 1.1.5 · checkedBASDAI disease activity questionnaire and spinal pain VASBath Ankylosing Spondylitis Disease Activity Index (BASDAI)NICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checkedOsteoporosis assessment (DEXA bone density scan)every 2 yearsNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checkedHLA-B27 blood testHLA-B27 testNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checkedMRI of spine and sacroiliac joints (inflammatory back pain protocol)unenhanced MRINICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checkedPlain X-ray of the sacroiliac jointsplain film X-rayNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checkedUltrasound of hands, feet and suspected enthesitis sitesultrasoundNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checkedPlain X-ray of symptomatic hands and feetplain film X-rayNICE NG65, Spondyloarthritis in over 16s: diagnosis and management, recommendations · checkedAnnual physical and mental health review with relevant blood tests (anorexia nervosa not in treatment)at least annuallyNICE NG69, Eating disorders: recognition and treatment, recommendation 1.10.10 · checkedBone mineral density scan in anorexia nervosaafter 2 years of underweight in adultsNICE NG69, Eating disorders: recognition and treatment, recommendation 1.10.15 · checkedECG monitoring while taking medication that could affect the heartOffer electrocardiogram (ECG) monitoringNICE NG69, Eating disorders: recognition and treatment, recommendation 1.8.17 · checkedFluid and electrolyte assessment in people who vomit or misuse laxatives or diureticsAssess fluid and electrolyte balanceNICE NG69, Eating disorders: recognition and treatment, recommendation 1.10.1 · checkedSelf-monitoring record of dietary intake and thoughts during CBT-ED for anorexia nervosaup to 40 sessions over 40 weeksNICE NG69, Eating disorders: recognition and treatment, recommendation 1.3.5 · checkedDiagnostic laparoscopy reportif imaging is normal but endometriosis is suspectedNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checkedSpecialist ultrasound or pelvic MRI for deep endometriosiswhen deep endometriosis is suspectedNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checkedTransvaginal ultrasound scanat suspected diagnosisNICE NG73, Endometriosis: diagnosis and management, section 1.5 · checkedGlaucoma reassessment visit for stable COAGbetween 12 months and 18 months (low risk), between 6 months and 12 months (high risk)NICE NG81, Glaucoma: diagnosis and management, recommendations · checkedOptic nerve head image (stereo photograph or OCT) at diagnosisat diagnosisNICE NG81, Glaucoma: diagnosis and management, recommendations · checkedProstaglandin analogue eye drop prescriptiongeneric PGANICE NG81, Glaucoma: diagnosis and management, recommendations · checkedReferral letter with all examination and test resultswith the referralNICE NG81, Glaucoma: diagnosis and management, recommendations · checkedIntravitreal anti-VEGF injection treatmentintravitreal anti-vascular endothelial growth factor (VEGF) treatmentNICE NG82, Age-related macular degeneration, recommendations · checkedFundus fluorescein angiography (FFA)to confirm the diagnosisNICE NG82, Age-related macular degeneration, recommendations · checkedOptical coherence tomography (OCT) for suspected wet AMDoptical coherence tomography (OCT)NICE NG82, Age-related macular degeneration, recommendations · checkedOngoing OCT monitoring of both eyes in wet AMDongoing monitoringNICE NG82, Age-related macular degeneration, recommendations · checkedPsARC response assessment on TNF inhibitor treatmentat 12 weeksNICE TA199, Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis · checkedOral bisphosphonate prescription (alendronate, ibandronate, risedronate)at least 5 yearsNational Osteoporosis Guideline Group, The 2024 UK clinical guideline for the prevention and treatment of osteoporosis, Arch Osteoporos 2025 · checkedRoutine blood tests at investigation (full blood count, vitamin D, thyroid function and others)Full blood cell countNational Osteoporosis Guideline Group, The 2024 UK clinical guideline for the prevention and treatment of osteoporosis, Arch Osteoporos 2025, Table 2 · checked12-week treatment review note (improvement and side effects)at 12 weeksNICE NG198, Acne vulgaris: management, section 1 · checkedDermatology referral or clinic letter for acne causing persistent psychological distresspersistent psychological distressNICE NG198, Acne vulgaris: management, section 1 · checkedMaintenance treatment reviewafter 12 weeksNICE NG198, Acne vulgaris: management, section 1 · checkedHeart rate and blood pressure monitoringevery 6 monthsNICE NG87 ADHD, recommendations · checkedADHD medication review (prescription history)at least once a yearNICE NG87 ADHD, recommendations · checkedSymptom and adverse effect rating scales (for example Conners' rating scales)standard symptom and adverse effect rating scalesNICE NG87 ADHD, recommendations · checkedCognitive and behavioural assessmentAt diagnosis, and if there is concern about cognition and behaviourNICE NG42, Motor neurone disease: assessment and management, section 1 · checkedMultidisciplinary team (MND clinic) assessment lettersTailor the frequency of the multidisciplinary team assessments to the person's symptoms and needsNICE NG42, Motor neurone disease: assessment and management, section 1 · checkedWeight, diet, nutrition and swallowing assessmentAt diagnosis and at multidisciplinary team assessmentsNICE NG42, Motor neurone disease: assessment and management, section 1 · checkedRespiratory function monitoring resultsAssess and monitor the person's respiratory function and symptoms.NICE NG42, Motor neurone disease: assessment and management, section 1 · checkedBlood and urine tests to exclude reversible causesblood and urine testsNICE NG97 Dementia, recommendations · checkedBrief cognitive test (for example 6CIT, Mini-Cog)validated brief structured cognitive instrumentNICE NG97 Dementia, recommendations · checkedStructural brain imaging (MRI or CT)structural imagingNICE NG97 Dementia, recommendations · checkedNeuropsychological testing reportneuropsychological testingNICE NG97 Dementia, recommendations · checkedAnxiety drug treatment review (prescription history), generalised anxiety disorderevery 3 months thereafterNICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checkedGAD-2 anxiety questionnaire2-item Generalized Anxiety Disorder scale (GAD-2)NICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checkedAnxiety drug treatment review (prescription history), panic disorder8- to 12-week intervalsNICE CG113 Generalised anxiety disorder and panic disorder in adults, recommendations · checkedAllergy tests, only when a food or inhalant allergy is suspectedmost children with mild atopic eczema do not need to have tests for allergiesNICE CG57 Atopic eczema in under 12s, recommendations · checkedRepeat prescription review (prescription history)at least once a yearNICE CG57 Atopic eczema in under 12s, recommendations · checkedSeverity and quality-of-life assessment (children)at each consultationNICE CG57 Atopic eczema in under 12s, recommendations · checkedSpine imaging in non-specialist settings, not routineDo not routinely offer imaging in a non-specialist settingNICE NG59 Low back pain and sciatica in over 16s, recommendations · checkedSpine MRI or imaging in specialist careonly if the result is likely to change managementNICE NG59 Low back pain and sciatica in over 16s, recommendations · checkedSTarT Back risk stratification questionnaireSTarT BackNICE NG59 Low back pain and sciatica in over 16s, recommendations · checkedAnnual physical health check blood tests (HbA1c or fasting glucose, lipid profile, liver, renal and thyroid function)at least annuallyNICE CG185 Bipolar disorder, recommendations · checkedAnnual review of treatment and care including medicationat least annuallyNICE CG185 Bipolar disorder, recommendations · checkedPlasma lithium levelweekly until the levels are stableNICE CG185 Bipolar disorder, recommendations · checkedPathology report with ER, PR and HER2 statusoestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)NICE NG101 Early and locally advanced breast cancer, recommendations · checkedMammogramannual mammography for 5 yearsNICE NG101 Early and locally advanced breast cancer, recommendations · checkedBreast MRI before surgeryMRI of the breastNICE NG101 Early and locally advanced breast cancer, recommendations · checkedBurnout questionnaire covering the three ICD-11 dimensions (exhaustion, cynicism, reduced efficacy)three dimensionsWHO, Burn-out an occupational phenomenon: International Classification of Diseases · checkedMaslach Burnout Inventory (Human Services Survey) score22-item surveyBurnout: A Review of Theory and Measurement (Edu-Pérez et al., Int J Environ Res Public Health 2022), section 6.2 · checkedCEA blood test follow-upfor the first 3 yearsNICE NG151 Colorectal cancer, recommendations · checkedCT scan of chest, abdomen and pelvis follow-upCT scan of the chest, abdomen and pelvisNICE NG151 Colorectal cancer, recommendations · checkedRAS and BRAF V600E mutation test (pathology)RAS and BRAF V600E mutationsNICE NG151 Colorectal cancer, recommendations · checkedRoutine clinic review (adults)every 3 to 6 months as adultsNICE NG78 Cystic fibrosis, recommendations · checkedCystic-fibrosis-related diabetes testannually from 10 years of ageNICE NG78 Cystic fibrosis, recommendations · checkedPulmonary monitoring review (adults with lung disease)at least every 3 monthsNICE NG78 Cystic fibrosis, recommendations · checkedAntidepressant medication review (prescription history)at least every 6 monthsNICE NG222 Depression in adults, recommendations · checkedWeight, renal and thyroid function and calcium levels while on lithiumat least every 6 monthsNICE NG222 Depression in adults, recommendations · checkedValidated symptom, function or disability measure (for example PHQ-9 questionnaire)validated measureNICE NG222 Depression in adults, recommendations · checkedGeneralized Joint Hypermobility 5-Point Questionnaire (5PQ)at least 2 positive itemsEhlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checkedBeighton score (generalized joint hypermobility examination)Beighton ScoreEhlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checkedCOL5A1 and COL5A2 gene test report (classical EDS)more than 90% of the patientsEhlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checkedEchocardiogram report (mitral valve prolapse, aortic root dilatation)Aortic root dilatation with Z-score >+2Ehlers-Danlos Society, 2017 International Classification of the Ehlers-Danlos Syndromes (slide set, 15 March 2017) · checkedDiagnostic checklist (modified ACR 2010 criteria, no tender point exam needed)(modified) ACR 2010 diagnostic criteriaClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checkedSelected laboratory tests to exclude another diseaseselected laboratory testsClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checkedFibromyalgia survey questionnaire (symptom severity and widespread pain index)fibromyalgia survey questionnaireClassification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines (Canadian, German, Israeli), Evid Based Complement Alternat Med 2013 · checkedHTT gene CAG repeat length test reportalleles with 40 or more repeats are fully penetrantBachoud-Lévi et al., International Guidelines for the Treatment of Huntington's Disease, Frontiers in Neurology 2019 · checkedMalnutrition screening (MUST) and weight recordsScreening tools for malnutrition [e.g., malnutrition Universal Screening Tool (MUST)] are recommended.Bachoud-Lévi et al., International Guidelines for the Treatment of Huntington's Disease, Frontiers in Neurology 2019 · checkedSwallowing assessment (speech and language therapist)Regular assessment of swallowing disorders should be provided throughout the progression of the diseaseBachoud-Lévi et al., International Guidelines for the Treatment of Huntington's Disease, Frontiers in Neurology 2019 · checkedCoeliac disease antibody test (EMA or TTG)antibody testing for coeliac diseaseNICE CG61 Irritable bowel syndrome in adults, recommendations · checkedC-reactive protein and ESR or plasma viscosityc-reactive protein (CRP)NICE CG61 Irritable bowel syndrome in adults, recommendations · checkedFull blood countfull blood count (FBC)NICE CG61 Irritable bowel syndrome in adults, recommendations · checkedAMH blood test or antral follicle count (ovarian reserve)AMH measurement or antral follicle count (AFC)NICE NG257 Fertility problems, investigation of fertility problems · checkedHysterosalpingography (HSG) tubal patency scanhysterosalpingography (HSG)NICE NG257 Fertility problems, investigation of fertility problems · checkedMid-luteal serum progesterone blood testmid-luteal phase of their cycle (day 21 of a 28-day cycle)NICE NG257 Fertility problems, investigation of fertility problems · checkedSemen analysisrepeat confirmatory testNICE NG257 Fertility problems, investigation of fertility problems · checkedContrast-enhanced chest CTcontrast-enhanced chest CT scanNICE NG122 Lung cancer, diagnosis and staging · checkedPathology report with tumour subtype and molecular markerstumour subtyping and assessment of molecular markersNICE NG122 Lung cancer, diagnosis and staging · checkedPET-CT before curative treatmentpositron emission tomography CT (PET-CT)NICE NG122 Lung cancer, diagnosis and staging · checkedANA, anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, antiphospholipid antibodies, C3 and C4 at baselineat baseline: ANA, anti-dsDNA, anti-Ro, anti-La, anti-RNP, anti-Sm, anti-phospholipid, C3, C4EULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checkedBlood cholesterol and glucose (cardiovascular risk check)at least once a yearEULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checkedRoutine labs in inactive disease: blood count, ESR, CRP, albumin, creatinine or eGFR, urinalysis, urine protein/creatinine ratioAt 6–12 months intervalsEULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checkedProtein/creatinine ratio, C3, C4, anti-dsDNA, urine microscopy and blood pressure in lupus nephropathyat least every 3 months for the first 2–3 yearsEULAR recommendations for monitoring patients with SLE in clinical practice and in observational studies (Mosca et al., Ann Rheum Dis 2010), Table of recommendations · checkedLyme ELISA blood testenzyme-linked immunosorbent assay (ELISA)NICE NG95 Lyme disease, recommendations · checkedIgM and IgG antibody ELISA (C6 ELISA)both IgM and IgG antibodiesNICE NG95, Lyme disease, section 1.2 Diagnosis · checkedLyme immunoblot testimmunoblot testNICE NG95 Lyme disease, recommendations · checkedRepeat Lyme ELISA 4 to 6 weeks after the first test4 to 6 weeks after the first ELISA testNICE NG95 Lyme disease, recommendations · checkedSynovial fluid or cerebrospinal fluid analysissynovial fluid aspirate or biopsy, or lumbar puncture for cerebrospinal fluid analysisNICE NG95, Lyme disease, section 1.2 Diagnosis · checkedPrimary care review of care and support plan, adultsat least once a yearNICE NG206 ME/CFS, recommendations · checkedReview of care and support plan, children and young peopleat least every 6 monthsNICE NG206 ME/CFS, recommendations · checkedExclusion blood tests (vitamin D, vitamin B12 and folate levels, 9am cortisol)vitamin D, vitamin B12 and folate levelsNICE NG206 ME/CFS, recommendations · checkedFasting blood glucosefasting blood glucoseKorean Society for the Study of Obesity, 2022 Update of Clinical Practice Guidelines for Obesity (J Obes Metab Syndr 2023), laboratory evaluation · checkedSerum lipid profileserum lipid profileKorean Society for the Study of Obesity, 2022 Update of Clinical Practice Guidelines for Obesity (J Obes Metab Syndr 2023), laboratory evaluation · checkedLiver function testsliver function testsKorean Society for the Study of Obesity, 2022 Update of Clinical Practice Guidelines for Obesity (J Obes Metab Syndr 2023), laboratory evaluation · checkedHeight, weight and waist circumference measurementsheight weight waist circumferenceNICE NG246 Overweight and obesity management, identifying and assessing · checkedWeight-management medicine response check (prescription history)less than 5% of the initial weight has been lost after 6 monthsNICE NG246 Overweight and obesity management, medicines and surgery · checkedRegular review of weight-management medicinesregular reviewNICE NG246 Overweight and obesity management, medicines and surgery · checkedClinical diagnosis note (age 45 or over, activity-related joint pain)Diagnose osteoarthritis clinically without imagingNICE NG226 Osteoarthritis in over 16s, recommendations · checkedJoint imaging (X-ray, MRI), not routineDo not routinely use imaging to diagnose osteoarthritisNICE NG226 Osteoarthritis in over 16s, recommendations · checkedTreatment reviewfrequency of reviews on clinical needNICE NG226 Osteoarthritis in over 16s, recommendations · checked123I-FP-CIT SPECT (DaTscan)123 I-FP-CIT single photon emission computed tomography (SPECT)NICE NG71 Parkinson's disease in adults, recommendations · checkedStructural MRI (not for diagnosis; for differential diagnosis)Structural MRI may be considered in the differential diagnosis of other parkinsonian syndromesNICE NG71 Parkinson's disease in adults, recommendations · checkedSpecialist review of diagnosisregular intervals of 6 to 12 monthsNICE NG71 Parkinson's disease in adults, recommendations · checkedBlood pressure measurementannuallyInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checkedGlycaemic status test (OGTT, fasting glucose or HbA1c)every one to three yearsInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checkedFasting lipid profilefasting lipid profileInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checkedOral glucose tolerance test (OGTT) when planning pregnancy24-28 weeksInternational evidence-based guideline for the assessment and management of PCOS 2023 (ESHRE, ASRM, Endocrine Society and partners) · checkedMultiparametric prostate MRImultiparametric MRI as the first-line investigationNICE NG131 Prostate cancer, recommendations · checkedPSA on intermittent androgen deprivation therapymeasure PSA every 3 monthsNICE NG131 Prostate cancer, recommendations · checkedPSA blood test after radical treatmentat least every 6 months for the first 2 years, and then at least once a yearNICE NG131 Prostate cancer, recommendations · checkedCardiovascular risk assessmentevery 5 yearsNICE CG153 Psoriasis: assessment and management, recommendations · checkedPASI severity score and DLQI quality-of-life questionnairePsoriasis Area and Severity Index (PASI)NICE CG153 Psoriasis: assessment and management, recommendations · checkedAnnual psoriatic arthritis assessmentannualNICE CG153 Psoriasis: assessment and management, recommendations · checkedReview of potent topical corticosteroid use (prescription history)at least annuallyNICE CG153 Psoriasis: assessment and management, recommendations · checkedBlood count with differential and reticulocytes on hydroxyureaat least every 4 weeksNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checkedUrine protein screenrepeat screening annuallyNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checkedTranscranial Doppler (TCD) ultrasoundscreen annually with TCDNHLBI Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014 · checkedCPAP usage data (telemonitoring)up to 12 monthsNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checkedEpworth Sleepiness Scale questionnaireEpworth Sleepiness ScaleNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checkedHome respiratory polygraphy sleep studyhome respiratory polygraphyNICE NG202 Obstructive sleep apnoea/hypopnoea syndrome, recommendations · checkedBlood glucose readings during the acute stroke admissionbetween 4 and 11 mmol/litreNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checkedBrain scan (CT or MRI) report after suspected strokewithin 24 hours of symptom onsetNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checkedCarotid imaging reporturgent carotid imagingNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checkedMRI report (diffusion-weighted and blood-sensitive sequences) after a TIAon the same day as the assessmentNICE NG128, Stroke and transient ischaemic attack in over 16s: diagnosis and initial management, section 1 · checkedBaseline CD4 cell countbaseline CD4 cell count testing should be performedWHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), rapid ART initiation · checkedDolutegravir-based first-line antiretroviral therapy prescriptionpreferred first-line regimenWHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), first-line ART · checkedHIV viral load test on antiretroviral therapyby six months, at 12 months and then every 12 months thereafterWHO Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (2021), timing of treatment monitoring · checked
Definitions (3)
EU definition of a rare disease: prevalence threshold for orphan medicinal product designationnot more than five in 10 thousand personsRegulation (EC) No 141/2000 on orphan medicinal products, Article 3(1)(a) · checkedWorld population8 billionUnited Nations, Global Issues: Population · checkedUS definition of a rare disease or condition under the Orphan Drug Actless than 200,000 persons in the United StatesFDA, Orphan Drug Act relevant excerpts (Section 526 of the FD&C Act) · checked
How the evidence is kept
- Every morning a research run re-reads every source and checks that its quoted words are still there.
- The same run looks for newer figures and fills gaps: new conditions people share about, prices the market publishes.
- A newer figure supersedes the old one; the old one stays here, so every past valuation stays explainable.
- Nothing enters without its source, its exact words and the day it was read.